Evidence mapPaperPMID 35955419Full record

ReviewInternational journal of molecular sciences2022

The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V.

Juan A De Pablo-Moreno, Luis Javier Serrano, Luis Revuelta, María José Sánchez, Antonio Liras

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 78 citations in OpenAlex.

  1. Integrated single-cell transcriptomic analysis identifiesBiochemistry and biophysics reports · 2026
    Article
  2. Article
  3. Article
  4. Novel insights of ferroptosis in atherosclerosis progression.Frontiers in cell and developmental biology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Juan A De Pablo-MorenoDepartment of Genetics, Physiology and Microbiology, School of Biology, Complutense University, 28040 Madrid, Spain.ORCID 0000-0002-9491-5572
Luis Javier SerranoDepartment of Genetics, Physiology and Microbiology, School of Biology, Complutense University, 28040 Madrid, Spain.ORCID 0000-0003-0363-3148
Luis RevueltaDepartment of Physiology, School of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
María José SánchezCentro Andaluz de Biología del Desarrollo (CABD), Consejo Superior de Investigaciones Científicas (CSIC), Junta de Andalucía, Pablo de Olavide University, 41013 Sevilla, Spain.ORCID 0000-0003-3464-6224
Antonio LirasDepartment of Genetics, Physiology and Microbiology, School of Biology, Complutense University, 28040 Madrid, Spain.
Universidad Complutense de Madrid · ESConsejo Superior de Investigaciones Científicas · ES

Funding

Association for Research and Cure of Factor V deficiency ASDEFAV/2021-23
6 · The paper itself

Abstract

The vascular endothelium has several important functions, including hemostasis. The homeostasis of hemostasis is based on a fine balance between procoagulant and anticoagulant proteins and between fibrinolytic and antifibrinolytic ones. Coagulopathies are characterized by a mutation-induced alteration of the function of certain coagulation factors or by a disturbed balance between the mechanisms responsible for regulating coagulation. Homeostatic therapies consist in replacement and nonreplacement treatments or in the administration of antifibrinolytic agents. Rebalancing products reestablish hemostasis by inhibiting natural anticoagulant pathways. These agents include monoclonal antibodies, such as concizumab and marstacimab, which target the tissue factor pathway inhibitor; interfering RNA therapies, such as fitusiran, which targets antithrombin III; and protease inhibitors, such as serpinPC, which targets active protein C. In cases of thrombophilia (deficiency of protein C, protein S, or factor V Leiden), treatment may consist in direct oral anticoagulants, replacement therapy (plasma or recombinant ADAMTS13) in cases of a congenital deficiency of ADAMTS13, or immunomodulators (prednisone) if the thrombophilia is autoimmune. Monoclonal-antibody-based anti-vWF immunotherapy (caplacizumab) is used in the context of severe thrombophilia, regardless of the cause of the disorder. In cases of disseminated intravascular coagulation, the treatment of choice consists in administration of antifibrinolytics, all-trans-retinoic acid, and recombinant soluble human thrombomodulin.

Indexed as

Thrombophiliavon Willebrand FactorAnticoagulantsEndothelium, VascularFactor VFactor VIIIHomeostasisHumansProtein CAnticoagulantsFactor VFactor VIIIProtein Cvon Willebrand Factorcoagulationcoagulopathiesembryofactor Vfactor VIIIhomeostasistreatmentvascular endotheliumvon Willebrand factor

Identifiers

PMID35955419
PMCPMC9425441
OpenAlexW4288066906

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.